Evofem Biosciences, Inc. (EVFM) |
|
0.0248 -0.01 (-29.14%)
|
03-24 15:59 |
|
Open: |
0.0321 |
Pre. Close: |
0.035 |
|
High:
|
0.04 |
Low:
|
0.0192 |
|
Volume:
|
17,174,669 |
Market Cap:
|
4(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:25:47 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 0.03 One year: 0.05 |
| Support: |
Support1: 0.01 Support2: 0.01 |
| Resistance: |
Resistance1: 0.03 Resistance2: 0.04 |
| Pivot: |
0.02 |
| Moving Average: |
MA(5): 0.02  MA(20): 0.02
MA(100): 0.05 MA(250): 0.61 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 73 %D(3): 70.2 |
| RSI: |
RSI(14): 44.5 |
| 52-week: |
High: 5.55 Low: 0.01 |
| Average Vol(K): |
3-Month: 3,669 (K) 10-Days: 7,718 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ EVFM ] has closed below upper band by 44.5%. Bollinger Bands are 2.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.04 - 0.04 |
0.04 - 0.04 |
|
Low:
|
0.02 - 0.02 |
0.02 - 0.02 |
|
Close:
|
0.02 - 0.02 |
0.02 - 0.03 |
|
Company Description |
|
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California. |
Headline News |
Thu, 23 Mar 2023
CapitalGainsReport: Thursday’s OTC Watchlist (EVFM, EPAZ, NWBO, VDRM) - Yahoo Finance
Tue, 21 Mar 2023
Evofem Biosciences Announces Cost Reduction Measures - PR Newswire
Tue, 14 Mar 2023
EVOFEM BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
Tue, 14 Mar 2023
Evofem Biosciences Inc. (OTCMKTS:EVFM) Appoints Interim Chief Financial Officer - Evofem Biosciences (OTC - Benzinga
Thu, 09 Mar 2023
Evofem Biosciences Appoints Interim Chief Financial Officer ... - Benzinga
Mon, 27 Feb 2023
Evofem Biosciences Announces FDA Orange Book Listing of Two ... - PR Newswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Outperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: PNK |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
170 (M) |
| Shares Float |
121 (M) |
|
% Held by Insiders
|
0.1 (%) |
|
% Held by Institutions
|
4.1 (%) |
|
Shares Short
|
8,680 (K) |
|
Shares Short P.Month
|
17,820 (K) |
Stock Financials |
|
EPS
|
-4.39 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-0.76 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-541.4 |
|
Return on Assets (ttm)
|
-124.8 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
272.1 |
|
Gross Profit (p.s.)
|
0.02 |
|
Sales Per Share
|
0.11 |
|
EBITDA (p.s.)
|
-0.64 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-85 (M) |
|
Levered Free Cash Flow
|
-36 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-0.04 |
|
Price to Sales
|
0.2 |
|
Price to Cash Flow
|
-0.05 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2018-01-17 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
